Biological and Clinical Markers to Differentiate the Type of Anxiety Disorders
Authors:
- 31 January 2020
- book chapter
- Published by Springer Nature
- Vol. 1191, 197-218
Abstract
The present chapter is an overview of possible biomarkers which distinguish anxiety disorders as classified by the DSM-5. Structural or activity changes in the brain regions; changes in N-acetylaspartate/creatine, dopamine, serotonin, and oxytocin; hearth rate variability; hypothalamic–pituitary–adrenal axis activity; error-related negativity; respiratory regulation; and genetic variants are proposed. However, their clinical utility is questionable due to low specificity and sensitivity: the majority does not distinguish subjects with different anxiety disorders, and they might be influenced by stress, comorbidity, physical activity, and psychotropic medications. In this framework, the staging model, a clinimetric tool which allows to define the degree of progression of a disease at a point in time and where the patient is located on the continuum of the course of the disease, is proposed since several DSM anxiety disorders take place at different stages of the same syndrome according to the staging model. Thus, a stage-specific biomarker model for anxiety disorders is hypothesized and illustrated.Keywords
This publication has 107 references indexed in Scilit:
- Reduced Heart Rate Variability in Social Anxiety Disorder: Associations with Gender and Symptom SeverityPLOS ONE, 2013
- A way forward for research on biomarkers for psychiatric disordersJournal of Psychiatry and Neuroscience, 2013
- How Biomarkers Will Change PsychiatryJournal of Psychiatric Practice, 2012
- Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorderThe British Journal of Psychiatry, 2011
- Glucocorticoids enhance extinction-based psychotherapyProceedings of the National Academy of Sciences, 2011
- Anticipatory Activation in the Amygdala and Anterior Cingulate in Generalized Anxiety Disorder and Prediction of Treatment ResponseAmerican Journal of Psychiatry, 2009
- Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorderPsychoneuroendocrinology, 2008
- A Functional Magnetic Resonance Imaging Predictor of Treatment Response to Venlafaxine in Generalized Anxiety DisorderBiological Psychiatry, 2008
- Protection and Damage from Acute and Chronic Stress: Allostasis and Allostatic Overload and Relevance to the Pathophysiology of Psychiatric DisordersAnnals of the New York Academy of Sciences, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001